Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01593722 (Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Preclinical animal models for onchocerciasis and loiasis: A systematic review of applications in drug screening.PLoS neglected tropical diseases · 2026Pooled it
- Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review.Parasites & vectors · 2025Pooled it
- Guideline
- Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial.PLoS neglected tropical diseases · 2025Trial
- The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Trial
- A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Major basic protein and eosinophil peroxidase support microfilariae motility inhibition by eosinophil ETosis.PLoS neglected tropical diseases · 2025Article
- Eosinophils, basophils and myeloid-derived suppressor cells in chronic Loa loa infection and its treatment in an endemic setting.PLoS neglected tropical diseases · 2024Article
- Eosinophils in filarial infections: Inducers of protection or pathology?Frontiers in immunology · 2022Review
- Eosinophils and helminth infection: protective or pathogenic?Seminars in immunopathology · 2021Review
- Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Imported loiasis in France: a retrospective analysis of 167 cases with comparison between sub-Saharan and non sub-Saharan African patients.BMC infectious diseases · 2020Article
- Approach to Patients with Eosinophilia.The Medical clinics of North America · 2020Review
- Mouse models of Loa loa.Nature communications · 2019Article
- Cervical Lymphatic Filariasis in a Pediatric Patient: Case Report and Database Analysis of Lymphatic Filariasis in the United States.The American journal of tropical medicine and hygiene · 2018Review
- Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.Parasites & vectors · 2018Article
- Reduction of Loa loa Microfilaremia with Imatinib - A Case Report.The New England journal of medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
Background: Severe adverse reactions have been observed in individuals with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis, or ivermectin (IVM), which is used in mass drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa. In this study, posttreatment clinical and immunologic reactions were compared following single-dose therapy with DEC or IVM to assess whether these reactions have the same underlying pathophysiology. Methods: Twelve patients with loiasis and microfilarial counts <2000 mf/mL were randomized to receive single-dose DEC (8 mg/kg) or IVM (200 µg/kg). Clinical and laboratory assessments were performed at 4, 8, 24, 48, and 72 hours and 5, 7, 9, and 14 days posttreatment. Results: Posttreatment adverse events were similar following DEC or IVM, but peaked earlier in subjects who received DEC, consistent with a trend toward more rapid and complete microfilarial clearance in the DEC group. After a transient rise (post-IVM) or fall (post-DEC) in the first 24 hours posttreatment, the eosinophil count rose significantly in both groups, peaking at day 5 in the DEC group and day 9 in the IVM group. Serum interleukin 5 levels and eosinophil activation, as assessed by surface expression of CD69 and serum levels of eosinophil granule proteins, were increased posttreatment in both groups. Conclusions: Despite differences in eosinophil and lymphocyte counts during the first 24 hours posttreatment, the overall pattern of hematologic and immunologic changes suggest that posttreatment reactions following DEC and IVM share a common pathophysiology. Clinical Trials Registration: NCT01593722.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.